Core Viewpoint - Concentra Group (CON) has experienced significant selling pressure, resulting in a 5.8% decline over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - CON's current RSI reading is 28.87, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. - RSI serves as a tool to identify potential price reversals, allowing investors to seek entry points for anticipated rebounds [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for CON, with a consensus EPS estimate increase of 0% over the last 30 days, which typically correlates with price appreciation [7]. - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Group 1 - Concentra Group (CON) has outperformed its Medical sector peers, gaining approximately 3.3% year-to-date, while the average loss for Medical stocks is 3.3% [4] - The Zacks Rank for Concentra Group is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for Concentra Group's full-year earnings has increased by 1.5% over the past three months, reflecting improved analyst sentiment [4] Group 2 - Concentra Group is part of the Medical Services industry, which consists of 58 stocks and currently ranks 65 in the Zacks Industry Rank, with an average loss of 2.4% year-to-date [6] - Boston Scientific (BSX), another Medical stock, has returned 15.3% year-to-date and has a Zacks Rank of 2 (Buy) [5] - The Medical - Products industry, to which Boston Scientific belongs, has moved up by 6.1% year-to-date and is currently ranked 152 [6]

Core Viewpoint - Concentra Group (CON) has seen a 2.9% increase in share price over the past four weeks, closing at $22.03, with a mean price target of $28 indicating a potential upside of 27.1% [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $25 to a high of $30, with a standard deviation of $1.85, suggesting a potential increase of 13.5% to 36.2% from the current price [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about CON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Company Overview - Benitec Biopharma Limited (BNTC) is a notable stock within the Medical sector, currently ranked 5 in the Zacks Sector Rank, which evaluates 16 different groups based on the average Zacks Rank of individual stocks [2] - BNTC has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings prospects [3] Performance Metrics - Over the past 90 days, the Zacks Consensus Estimate for BNTC's full-year earnings has increased by 61.8%, reflecting improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, BNTC has returned 7.7%, significantly outperforming the average return of -5.6% for Medical companies as a whole [4] - In the Medical - Biomedical and Genetics industry, which includes 506 stocks, BNTC is performing better than the average loss of 6.5% this year, currently ranked 77 in the Zacks Industry Rank [6] Comparative Analysis - Another outperforming stock in the Medical sector is Concentra Group (CON), which has returned 14.9% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Concentra Group belongs to the Medical Services industry, which has seen a year-to-date decline of -2.4% and consists of 58 stocks currently ranked 51 [6] Future Outlook - Investors interested in Medical stocks should monitor Benitec Biopharma Limited and Concentra Group for potential continued strong performance [7]

Summary of Concentra Group Holdings Parent (CON) 2025 Conference Call Company Overview - Concentra is the largest primary care provider of occupational health care services in the United States, focusing on workplace health and injury management [1][2] - The company treats approximately 20% of all workers' compensation injuries in the U.S., working with over 215,000 employers [3][4] Core Business Lines - **Workers' Compensation Services**: - Majority of visits are related to musculoskeletal injuries, with 40-50% referred to therapy [7][8] - Reimbursement is based on state fee schedules, which vary by state [10][11] - **Employer Services**: - Includes drug screenings and physicals, with direct negotiations for pricing with employers [12][9] - Services are fee-for-service, with no capitation or at-risk payments [13] - **On-site Services and Telemedicine**: - Concentra offers on-site health services at employer locations and a telemedicine platform, expanding their service offerings [16][17] Financial Performance and Growth Strategy - Revenue growth is targeted in the mid to high single digits, driven by same-center visits, pricing adjustments, and small acquisitions [18][21] - Workers' compensation volumes were flat in Q1, but positive growth was observed in subsequent months [22][23] - Employer Services experienced a decline post-COVID but showed signs of recovery with a 10-15% increase in volume [25][46] Market Dynamics - The company operates in a diversified market, with no single industry representing more than 10% of revenues [29] - Historical resilience during economic downturns, with modest declines in EBITDA during the global financial crisis [30][31] Pricing and Rate Adjustments - Workers' compensation rates are influenced by state fee schedules, with an average growth of 3% historically [19][37] - Approximately 20 states have a Consumer Price Index (CPI) or Medical Economic Index (MEI) tied to their fee schedules, allowing for potential rate increases in line with inflation [39][40] Future Outlook - Positive trends in both workers' compensation and employer services are expected to continue, contingent on economic stability [27][47] - The company is focused on integrating recent acquisitions and reducing leverage, targeting a leverage ratio of 3.0x within 18-24 months [62][63] Additional Insights - The company is exploring new service offerings, such as background checks, to enhance employer services [53] - Behavioral health services are being expanded through telemedicine, reflecting growing demand [59] This summary encapsulates the key points discussed during the conference call, highlighting Concentra's business model, financial performance, market dynamics, and future growth strategies.

Concentra Group (CON) closed the last trading session at $21.40, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28 indicates a 30.8% upside potential.The average comprises eight short-term price targets ranging from a low of $25 to a high of $30, with a standard deviation of $1.85. While the lowest estimate indicates an increase of 16.8% from the current price level, ...

Concentra Group Holdings Parent (CON) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants Keith Newton - CEOMatthew DiCanio - President & CFOBenjamin Rossi - Equity Research AssociateBen Hendrix - Vice PresidentEdward Kressler - Managing Director Conference Call Participants Jamie Perse - AnalystJoanna Gajuk - Equity Research AnalystStephen Baxter - Senior Equity Research AnalystJustin Bowers - Analyst Operator Good morning and thank you for joining us today for Concentra Group Holdings Pare ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $500.8 million, a 7.1% increase from $467.6 million in Q1 2024, representing an 8.9% growth rate on a revenue per day basis [8][12] - Adjusted EBITDA was $102.7 million, up 6.8% from $96.1 million in the same quarter last year, with a slight decrease in adjusted EBITDA margin from 20.6% to 20.5% [8][19] - Net income was $40.6 million, lower than the same quarter last year primarily due to increased interest expenses and transaction costs related to acquisitions [10][19] Business Line Data and Key Metrics Changes - Total patient visits per day increased 3.2% year over year to 50,900, with a 0.6% increase to 49,600 when excluding the Nova acquisition [5][12] - Workers' compensation revenue was $302.1 million, an 8% increase year over year, with visits per day up 2.4% [13] - Employer services revenue increased 6.2% to $160.1 million, with visits per day up 3.9%, marking a turnaround from previous declines [14][19] Market Data and Key Metrics Changes - The company reported strong growth in both workers' compensation and employer services, indicating a positive trend in visit volumes across all service lines [6][10] - The acquisition of Nova Medical Centers contributed positively to the company's performance, although it only accounted for one month of results in Q1 [4][10] Company Strategy and Development Direction - The company is focused on corporate development, having recently completed several acquisitions, including Nova and Physician Health Center, and is set to close the Pivot On-site acquisition [7][25] - The strategy includes expanding the on-site health clinics business, which is expected to double revenue in that segment and enhance overall service offerings [24][25] - The company aims to maintain a leverage ratio of approximately 3.5 times by the end of 2025 and is committed to deleveraging while focusing on organic growth initiatives [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the current macroeconomic environment, noting no observed impact on visit volumes despite broader economic uncertainties [28][29] - The company is well-positioned to handle potential economic slowdowns, leveraging its history of managing costs effectively during downturns [31][32] - Future growth is anticipated from potential increases in manufacturing jobs due to reshoring efforts, which could drive visit growth at the company's centers [30][32] Other Important Information - The company declared a cash dividend of $0.0625 per share, payable on May 29, 2025 [22] - The company ended Q1 2025 with a total debt balance of $1.6 billion and a cash balance of $52 million, with a net leverage ratio of 3.9 times [21] Q&A Session Summary Question: Discussion on Employer Services volumes and turnaround - Management noted that the turnaround in employer services was aided by improved sales and marketing efforts, leading to increased optimism among employers [38][40] Question: Future growth with recent acquisitions - Management highlighted that the acquisitions enhance partnerships within the managed care ecosystem, driving additional volume and growth opportunities [42][44] Question: Workers' compensation performance and outlook - Management acknowledged that while organic growth was slightly slower than expected, they anticipate continued positive growth in the future [51][52] Question: Impact of inflation on rates - Management indicated that rates typically adjust in line with inflation, with historical patterns showing timely updates to fee schedules [58][60] Question: Cost of services performance and labor efficiencies - Management confirmed that labor efficiencies and revenue increases contributed to lower costs as a percentage of revenue, with ongoing investments in technology to enhance efficiency [62][64] Question: Guidance update and acquisition impacts - Management clarified that the updated guidance includes contributions from recent acquisitions, with expectations for continued strong performance [66][68]

©2025 Concentra Inc. All rights reserved. Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to, financial guidance and other projections and forecasts. Forward looking statements include statements that are not historical facts and can be identified by terms such as "anticipate," ...

Concentra Group (CON) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.23%. A quarter ago, it was expected that this provider of occupational health services would post earnings of $0.16 per share when it actually produced earnings of $0.17, delivering a surprise of 6.25%.Over the la ...